In This Section

Program

Friday, March 13

Saturday, March 14

SUNDAY, March 15

Monday, March 16

Friday, March 13

REGISTRATION

3-7 p.m. | Great Room Pre-Function Area

WELCOME AND OPENING Keynote

5:30-7:30 p.m | Great Room

  • 5:30 p.m. | Welcome and Keynote Speaker Introduction
  • 5:35 p.m. | Carl H. June, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
  • 6:30 p.m. | Keynote Speaker Introduction
  • 6:35 p.m. | Getting to kidney cancer cures: Lessons from von Hippel-Lindau disease and other cancers
    William G. Kaelin, Dana-Farber Cancer Institute, Boston, Massachusetts

OPENING RECEPTION

7:30-9 p.m. | Industry

Saturday, March 14

CONTINENTAL BREAKFAST

7-8 a.m. | Studio 2-3

Plenary Session 1: Immunotherapy in Kidney Cancer

8-10 a.m. | Great Room

Session Chairs: David A. Braun, Yale School of Medicine, New Haven, Connecticut Kathleen Mahoney, Beth Israel Deaconess Medical Center, Boston, Massachusetts 

  • 8 a.m. | Metabolic mechanisms controlling T cell immunity to kidney cancer
    Haydn Kissick, Emory University, Atlanta, Georgia
  • 8:30 a.m. | Defining the determinants of anti-tumor immunity in renal cell carcinoma
    David A. Braun, Yale School of Medicine, New Haven, Connecticut
  • 9 a.m. | ERVs, epigenetics, and the stromal code: Unraveling predictors of immune checkpoint blockade in renal cell carcinoma
    Gabriel G. Malouf, IGBMC, Strasbourg, France
  • 9:30 a.m. | Exploiting HIF-driven endogenous retroviral neoantigens to advance kidney cancer immunotherapy*
    Qinqin Jiang, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 9:45 a.m. | Design of dual-targeted fine-tuned immune restoring (DFIR) CAR-T cell therapy to treat advanced renal cell carcinoma (RCC)*
    Yufei Wang, Dana-Farber Cancer Institute, Boston, Massachusetts

COFFEE BReak

10-10:30 a.m. | Foyer

Plenary Session 2: Targeting Tumor Metabolism in Kidney Cancer

10:30 a.m.-12:30 p.m. | Great Room

Session Chairs: Mei Y. Koh, The University of Utah, Salt Lake City, Utah, M. Celeste Simon, Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania  

  • 10:30 a.m. | Harnessing lipid metabolism to treat kidney cancer
    M. Celeste Simon, Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania
  • 11 a.m. | Computational strategies to interrogate kidney cancer metabolism
    Ed Reznik, Memorial Sloan Kettering Cancer Center, New York, New York
  • 11:30 a.m. | Metabolic determinants of cancer metastasis
    W. Kimryn Rathmell, The Ohio State University, Columbus, Ohio
  • 12 p.m. | Ferritin-dependent iron storage and ferritinophagy impact ferroptosis resistance in chromophobe renal cell carcinoma*
    Wafaa Bzeih, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts
  • 12:15 p.m. | Lipid auxotrophy underlies ferroptosis sensitivity in clear cell renal cell carcinoma*
    Ji-Young Kim, Memorial Sloan Kettering Cancer Center, New York City, New York

Lunch on Own / Free Time

12:30-2:30 p.m.

Plenary Session 3: New Paradigms on Kidney Cancer Treatments

2:30-4:30 p.m. | Great Room

Session Chairs: Scott Haake, Vanderbilt University Medical Center, Nashville, Tennessee, Eric Jonasch, UT MD Anderson Cancer Center, Houston, Texas  

  • 2:30 p.m. | Implementing pragmatic biomarker into clinical trial in RCC 
    Laurence Albiges, Gustave Roussy, Villejuif, France
  • 3 p.m. | Eric Jonasch, UT MD Anderson Cancer Center, Houston, Texas
  • 3:30 p.m. | Translating insights from the TME into novel therapies for kidney cancer
    David F. McDermott, Beth Israel Deaconess Medical Center, Boston, Massachusetts
  • 4 p.m. | APOE-mediated immune-metabolic reprogramming of macrophages drives lipid delivery to tumor cells in clear-cell renal cell carcinoma*
    Tien Hsu, China Medical University Yingcai Campus, Taichung City, Taiwan
  • 4:15 p.m. | Evidence for the involvement of HIF-2α biology in the clinical efficacy of casdatifan, a novel  HIF-2α inhibitor, in clear cell renal cell carcinoma (ccRCC)*
    Jonathan Yingling, Arcus Biosciences Inc, Hayward, California

Break

4:30-4:45

Spotlight Session 1: Proffered Talks from Highly Rated Abstracts

4:45-5:45 p.m. | Great Room

Session Chairs: Ruhee Dere, Baylor College of Medicine, Houston, Texas, Pengda Liu, UNC School of Medicine, Chapel Hill, North Carolina

  • 4:45 p.m. | Chronic cGAS activation drives immunosuppressive remodeling and resistance to antiangiogenic tyrosine kinase inhibitors in ccRCC*
    Hongchao He, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 5 p.m. | Single cell transcriptomic investigation of tumor-infiltrating CD8+ T cells in renal cell carcinoma (RCC) resistant to immune checkpoint inhibition (ICI)*
    Rishabh Rout, Yale University, New Haven, Connecticut
  • 5:15 p.m. | Spatial single-cell transcriptomics reveal targetable macrophage subsets associated with antiangiogenic therapy resistance in renal cell carcinoma*
    Xiande Liu, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 5:30 p.m. | Deciphering the mechanistic basis of HIFα paralog target selectivity in kidney cancer*
    Nitin H. Shirole, Dana-Farber Cancer Institute, Boston, Massachusetts

Poster Session A / Reception

5:45-7:15 p.m. | Industry

Evening off / Dinner on Own

7:15 p.m.

Sunday, March 15

CONTINENTAL BREAKFAST

7-8 a.m. | Studio 2-3

Plenary Session 4 : Modeling Kidney Cancer

8-10 a.m. | Great Room

Session Chairs: Kathryn Beckermann, Tennessee Oncology, Franklin, Tennessee , James Brugarolas, UT Southwestern Medical Center, Dallas, Texas

  • 8 a.m.
    James Brugarolas, UT Southwestern Medical Center, Dallas, Texas
  • 8:30 a.m. | Modeling and modulating antitumor immunity in human cancer tissues
    Daniela Thommen, Netherlands Cancer Institute, Amsterdam, Netherlands
  • 9 a.m. | Modeling rare kidney cancers: Elucidating pathogenesis and uncovering therapeutic vulnerabilities
    Pavlos Msaouel, UT MD Anderson Cancer Center, Houston, Texas
  • 9:30 a.m.  | Breakage of chromosome 3p initiates clear cell renal cell carcinoma evolution*
    Rashmi Dahiya, University of Texas Southwestern Medical Center, Dallas, Texas
  • 9:45 a.m. | Co-operation of vhl and pbrm1 in early ccRCC morphogenesis*
    Samvid Kurlekar, University of Oxford, Oxford, United Kingdom

coffee Break

10-10:30 a.m. | Foyer

Plenary Session 5: Tumor Evolutions, Chromosomal Instability and Metastatic Tissue Tropism in Kidney Cancer

10:30 a.m.-12:30 p.m. | Great Room

Session Chairs: Srinivas Malladi, University of Texas Southwestern Medical Center, Dallas, Texas, Samra Turajlic, The Francis Crick Institute, London, United Kingdom 

  • 10:30 a.m. | Samra Turajlic, The Francis Crick Institute, London, United Kingdom
  • 11 a.m. | Integrated modeling of bone metastasis to dissect and overcome cancer therapy failure
    Eleonora Dondossola, UT MD Anderson Cancer Center, Houston, Texas
  • 11:30 a.m. | Mapping metabolic vulnerabilities in metastatic ccRCC using patient-derived organoids
    Srinivas Malladi, University of Texas Southwestern Medical Center, Dallas, Texas
  • 12 p.m. |  Genetic evolution of sarcomatoid/rhabdoid de-differentiation in renal cancers*
    Natalie R. Abuelsamen, McGill University, Montreal, Quebec, Canada
  • 12:15 p.m. | Shared germline architecture across renal cell carcinoma, coronary artery disease, and clonal hematopoiesis implicates a regulatory haplotype at the TERT promoter*
    Maxine Sun, Dana-Farber Cancer Institute, Boston, Massachusetts

Lunch on Own / Free Time

12:30-2:30 p.m.

Plenary Session 6: Advances on Studying Oncogenes and Tumor Suppressors in Kidney Cancer

2:30-4:30 p.m. | Great Room

Session Chairs: Qing Zhang, UT Southwestern Medical Center, Dallas, Texas 

  • 2:30 p.m. | The role of hypoxia pathways in kidney cancer
    David Mole, University of Oxford, Oxford, United Kingdom
  • 3 p.m. | Therapeutic targeting of tumor suppressor signals in ccRCC
    Qing Zhang, UT Southwestern Medical Center, Dallas, Texas
  • 3:30 p.m. | Genetic approaches to target vulnerabilities in kidney cancer
    James Nathan, University of Cambridge, Cambridge, United Kingdom
  • 4 p.m. | Chromophobe RCC: From pathogenesis to therapy
    Elizabeth P. Henske, Harvard Medical School/Brigham and Women’s Hospital, Boston, Massachusetts

Break

4:30-4:45 p.m.

Spotlight Session 2: Proffered Talks from Highly Rated Abstracts

4:45-5:45 p.m. | Great Room

Session Chairs: Thomas Carroll, UT Southwestern, Dallas, Texas, Abhishek A. Chakraborty, Cleveland Clinic, Cleveland, Ohio 

  • 4:45 p.m. | Epigenetic dysfunction promotes dependence on the NF-I/A transcription factor in kidney cancer*
    Abhishek A. Chakraborty, Cleveland Clinic, Cleveland, Ohio
  • 5 p.m. | Functional loss of actin-regulatory protein Profilin1 in vascular endothelial cells promotes a T-cell supportive chemical milieu in kidney cancer in a TRIM24-dependent manner*
    Sudeep Kumar Maurya, University of Pittsburgh, Pittsburgh, Pennsylvania
  • 5:15 p.m. | Exploiting CDK4/6-mTORC1 dependency reveals synergistic therapeutic potential in translocation renal cell carcinoma*
    Shikha Gupta, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 5:30 p.m.  | Activity-based network analysis identifies NEK5 as a PROTAC-targetable vulnerability in ccRCC*
    Cheng Zhang, UT Southwestern Medical Center, Dallas, Texas

Poster Session B / Reception

5:45-7:15 p.m. | Industry

Evening off / Dinner on Own

7:15 p.m.

Monday, March 16

CONTINENTAL BREAKFAST

7-8 a.m. | Studio 2-3

Plenary Session 7: Subtypes of Kidney Cancer and Therapeutic Implications

8-10 a.m.

Session Chairs: Elizabeth P. Henske, Harvard Medical School/Brigham and Women’s Hospital, Boston, Massachusetts, Srinivas R. Viswanathan, Dana-Farber Cancer Institute, Boston, Massachusetts 

  • 8 a.m. | Targeting protein phosphatase 5 to overcome drug resistance in ccRCC
    Mehdi Mollapour, SUNY Upstate Medical University, Syracuse, New York
  • 8:30 a.m. | Targeting purine salvage dependence in FH-deficient kidney cancer
    Heather R. Christofk, UCLA David Geffen School of Medicine, Los Angeles, California
  • 9 a.m. | From genomics to therapy: Mapping vulnerabilities in translocation renal cell carcinoma
    Srinivas R. Viswanathan, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 9:30 a.m. | Integrative multi-omic profiling reveals immune microenvironment subtypes in renal cell carcinoma*
    Keith Lawson, University Health Network, Toronto, Ontario, Canada
  • 9:45 a.m. | Targeting cadherin-17 in translocation renal cell carcinoma*
    Prateek Khanna, Dana-Farber Cancer Institute, Boston, Massachusetts

Break

10-10:30 a.m.

Plenary Session 8: Targeting Epigenetics in Kidney Cancer

10:30 a.m.-12:30 p.m. | Great Room

Session Chairs: Cheryl L. Walker, Baylor College of Medicine, Houston, Texas, Katherine Alexander, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York

  • 10:30 a.m. | Nuclear speckles in ccRCC
    Katherine Alexander, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
  • 11 a.m. | Non-canonical functions of epigenetic targets in RCC
    Cheryl L. Walker, Baylor College of Medicine, Houston, Texas
  • 11:30 a.m. | Transcriptional control of renal carcinogenesis
    Sakari Vanharanta, University of Helsinki, Helsinki, Finland
  • 12 p.m. | PBRM1-deficient PBAF complexes target aberrant genomic loci to activate the NF-κB pathway in clear cell renal cell carcinoma
    Bin T. Teh, National Cancer Centre Singapore, Singapore, Singapore

Closing Remarks

12:30 p.m.

  • Eric Jonasch, UT MD Anderson Cancer Center, Houston, Texas
  • M. Celeste Simon, Abramson Family Cancer Research Institute, Philadelphia, Pennsylvania
  • Samra Turajlic, The Francis Crick Institute, London, England
  • Qing Zhang, UT Southwestern Medical Center, Dallas, Texas